
Safusidenib showed durable responses in IDH1-mutant glioma, and ongoing trials will test the agent in oligodendroglioma, after vorasidenib, and as maintenance.
Note:These supplemental figures provide concrete illustrations of a
over 15 years ago
Management of DCIS-A Work in Progressover 15 years ago
Tailored Strategies for DCIS Managementover 15 years ago
Neuroendocrine Tumors: a Heterogeneous Set of Neoplasmsover 15 years ago
Can We Know What to Do When DCIS Is Diagnosed?over 15 years ago
A Rare Case of Metastatic Renal Epithelioid Angiomyolipomaover 15 years ago
The Changing Field of Locoregional Treatment for Breast Cancerover 15 years ago
Cancer and Healthcare Reform: Making the Pieces Fitover 15 years ago
An Approach to the Management of Rare Tumors





